Project Grant R35HL176060
Award Date
4/15/25
Completion Date
1/31/32
Dollars Obligated
$1.1M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under CFDA Program 93.837 - Cardiovascular Diseases Research, provides $717,246.00 to The Leland Stanford Junior University to conduct research aimed at elucidating the molecular mechanisms underlying cardiovascular toxicity associated with the cancer drug carfilzomib (CFZ). The project will leverage a humanized multiple myeloma mouse model, human induced...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), will support research at the University of Chicago to identify genetic biomarkers that can predict cancer patients' susceptibility to drug-induced cardiovascular toxicity. The research will involve single-cell RNA sequencing of cardiac cell cultures to assess the effects of cancer drugs like doxorubicin, 5-fluorouracil, and bevacizumab. The goal...
This Project Grant award for $827,665 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837). The award aims to develop scalable methods to address key challenges in cardiovascular disease (CVD) genome-wide association studies. Specifically, the grant will fund research to: 1) identify causal genetic variants associated with CVD, 2) determine the most relevant cell types for these variants, and 3)...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides USD $117,804 to The Leland Stanford Junior University to investigate the role of macrophages and T-cell recruitment in immune checkpoint inhibitor (ICI)-induced myocarditis. The project aims to characterize the mechanistic effects of blocking the CXCR3 receptor and its ligands CXCL9/10 on macrophage-mediated T-cell migration...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $433,824 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to The Leland Stanford Junior University. The grant, which runs from September 6, 2024 to March 31, 2026, supports research to understand the metabolic interplay between different cell types (cardiomyocytes, endothelial cells, fibroblasts) in a human induced pluripotent stem cell (iPSC) model of diabetic cardiomyopathy. The project aims to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $159,512 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University, also known as Stanford University. The grant supports research to investigate the role of the unfolded protein response in genetic dilated cardiomyopathy, a leading cause of heart failure. The project will utilize induced pluripotent stem cell-derived cardiomyocytes carrying DCM mutations to study the...
This $167,864 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, supports a research study to investigate risk stratification and outcomes across the spectrum of cardiotoxicity caused by immune checkpoint inhibitor (ICI) cancer therapies. The key objectives are to: 1) retrospectively examine cardiac and oncologic outcomes associated with ICI cardiotoxicity based on patient symptoms and...
This federal Project Grant award of $813,042.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on developing an integrative causal machine learning platform to predict and mitigate hematologic adverse events in patients with myeloid malignancies. The project aims to leverage advanced causal inference methods and machine learning to identify key predictors of thrombosis and quantify bleeding risk, ultimately...
This federal Project Grant award of $149,948.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on investigating the role of p53 in endothelial homeostasis after ionizing radiation exposure. The award aims to utilize human-induced pluripotent stem cells (iPSCs) and transgenic mouse models to study the impact of TP53 mutations on endothelial-to-mesenchymal transition and vascular function after radiation...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $299,604 Project Grant to Case Western Reserve University (CWRU) to develop and validate a novel "transfer volume regression" machine learning model for predicting major cardiovascular events, including stroke, heart attack, heart failure, and death. The 4-year project, starting September 1, 2024, aims to create a standardized, fairness-aware,...